Advanced glycation endproducts induce a proliferative response in vascular smooth muscle cells via altered calcium signaling

Biochemical Pharmacology

Volumn 76, Issue 9, 2008, Pages 1110-1120

  David, Kanola C ^a   Scott, Roderick H ^a   Nixon, Graeme F ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Calcium; Diabetes; Glycation; Proliferation; Vascular smooth muscle

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CAFFEINE; CALCINEURIN; CYCLOSPORIN A; GLYCOSYLATED ALBUMIN; ION CHANNEL; RYANODINE; RYANODINE RECEPTOR; SPHINGOSINE 1 PHOSPHATE; TRANSCRIPTION FACTOR NFAT;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM HOMEOSTASIS; CALCIUM SIGNALING; CALCIUM TRANSPORT; CELL PROLIFERATION; CONTROLLED STUDY; DIABETIC MICROANGIOPATHY; GLUCOSE BLOOD LEVEL; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; SWINE; VASCULAR SMOOTH MUSCLE;

ANIMALS; CALCIUM; CALCIUM SIGNALING; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; GLYCOSYLATION END PRODUCTS, ADVANCED; INTRACELLULAR FLUID; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; SWINE; UP-REGULATION;

EID: 53649083131     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.08.011     Document Type: Article

References (58)

1. Hanssen K.F. Blood glucose control and microvascular and macrovascular complications. Diabetes 46 (1997) S101-S103
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 1993;329:977-86.
3. Beckman J.A., Creager M.A., and Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287 (2002) 2570-2581
4. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001) 813-819
5. Cameron N.E., Cotter M.A., Basso M., and Hohman T.C. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 40 (1997) 271-281
6. Lee A.Y., and Chung S.S. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J 13 (1999) 23-30
7. Kuboki K., Jiang Z.Y., Takahara N., Ha S.W., Igarashi M., Yamauchi T., et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 101 (2000) 676-681
8. Sayeski P.P., and Kudlow J.E. Glucose metabolism to glucosamine is necessary for glucose stimulation of transforming growth factor-α gene transcription. J Biol Chem 271 (1996) 15237-15243
9. Wells L., and Hart G. O-GlcNAc turns twenty: functional implications for posttranslational modification of nuclear and cytosolic protein with a sugar. FEBS Lett 546 (2003) 154-158
10. Goldin A., Beckman J.A., Schmidt A.M., and Creager M.A. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114 (2006) 597-605
11. Hudson B.I., Wendt T., Bucciarelli L.G., Rong L.L., Naka Y., Yan S.F., and Schmidt A.M. Diabetic vascular disease: it's all the RAGE. Antioxid Redox Signal 7 (2005) 1588-1600
12. Thomas M.C., Baynes J.W., Thorpe S.R., and Cooper M.E. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets 6 (2005) 453-474
13. Thornalley P.J. The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. Biochem J 269 (1990) 1-11
14. Baynes J.W., and Thorpe S.R. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48 (1999) 1-9
15. Lyon T., and Jenkins A.J. Glycation, oxidation and lipoxidation in the development of the complications of diabetes mellitus; a carbonyl stress hypothesis. Diabetes Rev 5 (1997) 365-391
16. Ahmed N., and Thornalley P.J. Advanced glycation endproducts: what is their relevance to diabetic complications?. Diabetes Obes Metab 9 (2007) 233-245
17. Jakus V., and Reitbrock N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res 53 (2004) 131-142
18. Berg T.J., Dahl-Jorgensen K., Torjesen P.A., and Hanssen K.F. Increased serum levels of advanced glycation endproducts in children and adolescents with IDDM. Diabetes Care 20 (1997) 1006-1008
19. Nakamura S., Makita Z., Ishikawa S., Yasumura K., Fujii W., Yanagisawa K., et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46 (1997) 895-899
20. Hammes H.P., Martin S., Federlin K., Geisen K., and Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 88 (1991) 11555-11559
21. Zhou Z., Wang K., Penn M.S., Marso S.P., Lauer M.A., Forudi F., et al. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation 107 (2003) 2238-2243
22. Kislinger T., Tanji N., Wendt T., Qu W., Lu Y., Ferran Jr. L.J., et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 21 (2001) 905-910
23. Satoh H., Togo M., Hara M., Miyata T., Han K., Maekawa H., et al. Advanced glycation endproducts stimulate mitogen-activated protein kinase and proliferation in rabbit vascular smooth muscle cells. Biochem Biophys Res Commun 239 (1997) 111-115
24. Hattori Y., Suzuki M., Hattori S., and Kasai K. Vascular smooth muscle cell activation by glycated albumin (Amadori adducts). Hypertension 39 (2002) 22-28
25. Neeper M., Schmidt A.M., Brett J., Yan S.D., Wang F., Pan Y.C., et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267 (1992) 14998-15004
26. Brett J., Schmidt A.M., Yan S.D., Zou Y.S., Weidman E., Pinsky D., et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143 (1993) 1699-1712
27. Schmidt A.M., Yan S.D., Yan S.F., and Stern D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108 (2001) 949-955
28. Yonekura H., Yamamoto Y., Sakurai S., Petrova R.G., Abedin M.J., Li H., et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370 (2003) 1097-1109
29. Bierhaus A., Humpert P.M., Morcos M., Wendt T., Chavakis T., Arnold B., et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83 (2005) 876-886
30. Schiekofer S., Andrassy M., Chen J., Rudofsky G., Schneider J., Wendt T., et al. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. Diabetes 52 (2003) 621-633
31. Bierhaus A., Illmer T., Kasper M., Luther T., Quehenberger P., Tritschler H., et al. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 96 (1997) 2262-2271
32. ras-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 272 (1997) 17810-17814
33. Park L., Raman K.G., Lee K.J., Lu Y., Ferran Jr. L.J., Chow W.S., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4 (1998) 1025-1031
34. Sakaguchi T., Yan S.F., Yan S.D., Belov D., Rong L.L., Sousa M., et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 111 (2003) 959-972
35. 2+ to CREB activation and gene expression in intact cerebral arteries from mouse. Circ Res 86 (2000) 760-767
36. 2+ signaling and control of growth and proliferation. Biol Cell 96 (2004) 55-68
37. 2+ regulation. Cardiovasc Res 67 (2005) 308-316
38. Petrova R., Yamamoto Y., Muraki K., Yonekura H., Sakurai S., Watanabe T., et al. Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J Mol Cell Cardiol 34 (2002) 1425-1431
39. - currents in cultured rat sensory neurones by flash photolysis of DM-nitrophen. J Physiol 482 (1995) 291-307
40. Zhang L., Zalewski A., Liu Y., Mazurek T., Cowan S., Martin J.L., et al. Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries. Circulation 108 (2003) 472-478
41. Negoro H., Morley J.E., and Rosenthal M.J. Utility of serum fructosamine as a measure of glycemia in young and old diabetic and non-diabetic subjects. Am J Med 85 (1988) 360-364
42. Coussin F., Scott R.H., Wise A., and Nixon G.F. Comparison of sphingosine 1-phosphate-induced intracellular signaling pathways in vascular smooth muscles: differential role in vasoconstriction. Circ Res 91 (2002) 151-157
43. Tones M.A., Bootman M.D., Higgins B.F., Lane D.A., Pay G.F., and Lindahl U. The effect of heparin on the inositol 1,4,5-trisphosphate receptor in rat liver microsomes. FEBS Lett 252 (1989) 105-108
44. Hogan P.G., Chen L., Nardone J., and Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 17 (2003) 2205-2232
45. Yellaturu C.R., Ghosh S.K., Rao R.K., Jennings L.K., Hassid A., and Rao G.N. A potential role for nuclear factor of activated T-cells in receptor tyrosine kinase and G-protein-coupled receptor agonist-induced cell proliferation. Biochem J 368 (2002) 183-190
46. Cohen M.P., Clements R.S., Cohen J.A., and Shearman C.W. Glycated albumin promotes a generalized vasculopathy in the db/db mouse. Biochem Biophys Res Commun 218 (1996) 72-75
47. Clements Jr. R.S., Robison Jr. W.G., and Cohen M.P. Anti-glycated albumin therapy ameliorates early retinal microvascular pathology in db/db mice. J Diabetes Complicat 12 (1998) 28-33
48. Valencia J.V., Weldon S.C., Quinn D., Kiers G.H., DeGroot J., TeKoppele J.M., et al. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics. Anal Biochem 324 (2004) 68-78
49. Ramasamy R., Yan S.F., and Schmidt A.M. Arguing for the motion: yes, RAGE is a receptor for advanced glycation endproducts. Mol Nutr Food Res 51 (2007) 1111-1115
50. Tanaka N., Yonekura H., Yamagishi S., Fujimori H., Yamamoto Y., and Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 275 (2000) 25781-25790
51. 2+ distribution. Diabetes 48 (1999) 1323-1330
52. 2+-release channels. Cell Calcium 32 (2002) 307-319
53. Kinnear N.P., Wyatt C.N., Clark J.H., Calcraft P.J., Fleischer S., Jeyakumar L.H., et al. Lysosomes co-localize with ryanodine receptor subtype 3 to form a trigger zone for calcium signalling by NAADP in rat pulmonary arterial smooth muscle. Cell Calcium 44 (2008) 190-201
54. 2+ signals and immunosuppression. Nature 383 (1996) 837-840
55. Yu H., Sliedregt-Bol K., Overkleeft H., van der Marel G.A., van Berkel T.J., and Biessen E.A. Therapeutic potential of a synthetic peptide inhibitor of nuclear factor of activated T cells as antirestenotic agent. Arterioscler Thromb Vasc Biol 26 (2006) 1531-1537
56. Nilsson L.M., Sun Z.W., Nilsson J., Nordström I., Chen Y.W., Molkentin J.D., et al. Novel blocker of NFAT activation inhibits IL-6 production in human myometrial arteries and reduces vascular smooth muscle cell proliferation. Am J Physiol Cell Physiol 292 (2007) C1167-C1178
57. Liu Z., Zhang C., Dronadula N., Li Q., and Rao G.N. Blockade of nuclear factor of activated T cells activation signaling suppresses balloon injury-induced neointima formation in a rat carotid artery model. J Biol Chem 280 (2005) 14700-14708
58. Wada H., Hasegawa K., Morimoto T., Kakita T., Yanazume T., Abe M., et al. Calcineurin-GATA-6 pathway is involved in smooth muscle-specific transcription. J Cell Biol 156 (2002) 983-991